Pfizer Revises 2025 Revenue Guidance to $62 Billion

Pfizer ( (PFE) ) has provided an announcement.

On December 16, 2025, Pfizer announced its financial guidance for the full year 2026, while revising its 2025 revenue guidance to approximately $62.0 billion. The company expects 2026 revenues to range between $59.5 and $62.5 billion, with a decrease in COVID-19 product revenues and impacts from loss of exclusivity on certain products. Pfizer anticipates continued investment in its pipeline and acquired assets to fuel long-term growth, with adjusted diluted EPS for 2026 projected between $2.80 and $3.00. The financial outlook reflects Pfizer’s strategic focus on innovative medicines and vaccines, aiming to create long-term value for shareholders.

The most recent analyst rating on (PFE) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Pfizer stock, see the PFE Stock Forecast page.

Spark’s Take on PFE Stock

According to Spark, TipRanks’ AI Analyst, PFE is a Outperform.

Pfizer’s overall stock score reflects strong technical momentum and a solid valuation with an attractive dividend yield. Financial performance is stable but faces challenges in revenue growth and profitability. The earnings call provided positive guidance and strategic initiatives, though declining COVID-19 revenues and legal challenges with the Metsera acquisition pose risks. Overall, Pfizer is positioned well for long-term growth, but short-term challenges remain.

To see Spark’s full report on PFE stock, click here.

More about Pfizer

Pfizer Inc. is a leading pharmaceutical company involved in the development and manufacturing of healthcare products, including innovative medicines and vaccines. The company focuses on advancing its research and development pipeline to drive long-term growth and sustain its market position.

Average Trading Volume: 68,165,986

Technical Sentiment Signal: Hold

Current Market Cap: $147B

See more data about PFE stock on TipRanks’ Stock Analysis page.